BCL2L11 and cancer: The approval and use of the BCL-2:BIM complex-disrupting Venetoclax has heightened interest in finding precision medicine tools that could measure priming and, in doing this, identify cancer cells dependencies as vulnerabilities that could be addressed with therapy.